Oda N, et al. - Among patients with non-small-cell lung cancer (NSCLC) with a sensitive non-T790M epidermal growth factor receptor (EGFR) mutation, researchers assessed the effectiveness of EGFR-tyrosine kinase inhibitor (TKI) readministration with afatinib in those treated with cytotoxic chemotherapy after developing resistance to EGFR-TKIs. Eligible participants had EGFR-mutant tumors resistant to first- or second-generation EGFR-TKIs and an EGFR-TKI-free period with cytotoxic agents. The estimated objective response rate was 17% and the disease control rate was 84%. They observed modest activity and tolerable toxicity with EGFR-TKI readministered with afatinib for sensitive EGFR-mutant NSCLC without T790M after resistance to a first- or second-generation EGFR-TKI. According to findings, for patients who do not possess T790M tumors, it might be one of the treatment options.